AI-Driven Mass Spec Proteomics Platform

 

Category: Biotech Service

Exhibitor: MARKER X CO., LTD.

Booth No: N602

 

Characteristic

 

Why Choose the AI-Driven Mass Spec Proteomics Platform by MarkerX? Four Core Technological Breakthroughs

The AI-Driven Mass Spec Proteomics Platform, showcased by MarkerX, delivers versatile, ultra-deep multi-omics capabilities through a comprehensive, one-stop solution, successfully transforming high-resolution liquid chromatography-tandem mass spectrometry (LC-MS/MS) into a powerful asset for clinical translational research. The four core breakthroughs featured in this platform include:

1. Intelligent Nanoparticle De-noising Technology: Effective Elimination of Plasma Background Interference
Integrating cutting-edge ligand-nanoparticle optimization technology from US-based Nanomics, the platform achieves unparalleled selectivity in capturing low-abundance target proteins. Validated by Gene Ontology (GO) enrichment analysis, this approach efficiently isolates and suppresses high-abundance hydrolase background noise associated with complements and coagulation factors. This unlocks critical core protein signals linked to cell binding and signal transduction, drastically expanding the analytical depth of our proteomics analysis service.

2. Advanced Patient Stratification & Dynamic Longitudinal Disease Tracking
Leveraging the latest clinical research data, the platform has demonstrated remarkable success in deep plasma proteomic analysis involving neurodegenerative disease cohorts and age-matched healthy controls. It effectively screens and identifies highly significant differentially expressed specific biomarkers, providing high-value translational medicine insights for clinical biomarker discovery and robust disease stratification.

3. Unlocking Highly Challenging Degradative Specimens: Next-Gen FFPE Proteomics
Our proprietary FFPE proteomics analysis workflow successfully extracts and reconstructs complete, high-fidelity molecular signals from formalin-fixed paraffin-embedded (FFPE) tissue samples that are highly degraded or have been stored for years. This methodology resolves a long-standing clinical bottleneck, yielding exceptionally deep, publication-ready datasets for clinical pathology, translational medicine, and phosphoproteomics analysis.

4. Digital Molecular Weight Measurement: Overcoming the Limitations of Traditional IHC
By coupling laser capture microdissection (LCM) with high-end tandem mass spectrometry, this quantitative mass spectrometry platform replaces conventional immunohistochemistry (IHC) and its inherent clinical pain points—such as subjective visual scoring, antibody non-specific binding, and false-negative risks. It provides unbiased, data-driven mass spec molecular phenotyping, offering an objective, highly precise reference of molecular profiles for biotech contract research and advanced clinical trials.

 

Other Products

 

• 

  MyeloTrak

 

 

 

Back